The Weekly Litigation News Digest is now live. Subscribe now

IP Verse

Eisai R&d Management competitive analysis

Loading summary...

Latest patents of Eisai R&d Management opposed by its competitors

Explore Eisai R&d Management's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Nov 13, 2025
Patent NumberPublication DateTitleTotal Oppositions
EP3861346
Jan 8, 2025Biomarkers For A Therapy Comprising A Sorafenib Compound1
EP3581183
Nov 29, 2023Tumor-Treating Pharmaceutical Composition1
EP3263106
Oct 25, 2023Method For Suppressing Bitterness Of Quinoline Derivative8
EP3524595
Aug 10, 2022High-Purity Quinoline Derivative And Method For Manufacturing Same10
EP3265122
May 4, 2022Combination Of A Pd-1 Antagonist And Eribulin For Treating Cancer4
EP3338779
Jun 30, 2021Tumor Therapeutic Agent1

Latest PTAB cases involving Eisai R&d Management

Discover the latest PTAB cases involving Eisai R&d Management, highlighting their recent legal challenges and patent disputes.

Peer Comparison New

IP litigation analysis comparing Eisai R&d Management with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Nov 13, 2025
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
EISAI R&D MANAGEMENT - 25 - -
ACCORD HEALTHCARE39 - 4 -
GENERICS UK214 - - -
STADA ARZNEIMITTEL11028 - -